Psi Technical Specs V30a.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

Psi Technical Specs V30a.Pdf AHRQ Quality Indicators Patient Safety Indicators: Technical Specifications Department of Health and Human Services Agency for Healthcare Research and Quality http://www.qualityindicators.ahrq.gov March 2003 Version 3.0a (May 1, 2006) AHRQ Quality Indicators Web Site: http://www.qualityindicators.ahrq.gov Table of Contents Complications of Anesthesia (PSI 1) ............................................................................................................ 1 Death in Low-Mortality DRGs (PSI 2) ........................................................................................................... 3 Decubitus Ulcer (PSI 3) ................................................................................................................................. 5 Failure to Rescue (PSI 4) .............................................................................................................................. 7 Foreign Body Left during Procedure, Secondary Diagnosis Field (PSI 5 and 21)...................................... 14 Iatrogenic Pneumothorax, Secondary Diagnosis Field (PSI 6 and 22)....................................................... 15 Selected Infections Due to Medical Care, Secondary Diagnosis Field (PSI 7 and 23) .............................. 21 Postoperative Hip Fracture (PSI 8) ............................................................................................................. 21 Postoperative Hemorrhage or Hematoma (PSI 9 and 27) .......................................................................... 25 Postoperative Physiologic and Metabolic Derangement (PSI 10) .............................................................. 27 Postoperative Respiratory Failure (PSI 11) ................................................................................................ 29 Postoperative Pulmonary Embolism or Deep Vein Thrombosis (PSI 12) ................................................... 30 Postoperative Sepsis (PSI 13) .................................................................................................................... 30 Postoperative Wound Dehiscence (PSI 14 and 24)) .................................................................................. 31 Accidental Puncture or Laceration, Secondary Diagnosis Field (PSI 15 and 25)....................................... 38 Transfusion Reaction, Secondary Diagnosis Field (PSI 16 and 26) ........................................................... 38 Birth Trauma―Injury to Neonate (PSI 17) .................................................................................................. 39 Obstetric Trauma―Vaginal Delivery with Instrument (PSI 18) ................................................................... 41 Obstetric Trauma―Vaginal Delivery without Instrument (PSI 19) .............................................................. 42 Obstetric Trauma―Cesarean Delivery (PSI 20) ......................................................................................... 43 Appendix A: Operating Room Procedure Codes ..................................................................................... A-1 Appendix B: Surgical Discharge DRGs .................................................................................................... B-1 Appendix C: ICD-9-CM Trauma Diagnosis Codes................................................................................... C-1 Appendix D: ICD-9-CM Codes for Immunocompromised States ............................................................. D-1 Appendix E: Cancer Codes ...................................................................................................................... E-1 Appendix F: Medical Discharge DRGs ..................................................................................................... F-1 Appendix G: Hemorrhage Diagnosis Codes ............................................................................................. G-1 Appendix H: Shock Diagnosis Codes ...................................................................................................... H-1 Appendix I: ICD-9-CM Gastrointestinal (GI) Hemorrhage Diagnosis Codes ............................................ I-1 Appendix J: Trauma DRGs ....................................................................................................................... J-1 Appendix K: Pulmonary Embolism/Deep Vein Thrombosis Diagnosis Codes ........................................ K-1 Appendix L: Self-Inflicted Injury Diagnosis Codes .................................................................................... L-1 Appendix M: Acute Myocardial Infarction (AMI) Diagnosis Codes .......................................................... M-1 Appendix N: Cardiac Arrhythmia Diagnosis Codes ................................................................................. N-1 Appendix O: Sepsis Diagnosis Codes ..................................................................................................... O-1 Appendix P: Infection Diagnosis Codes and DRGs ................................................................................. P-1 Appendix Q: Cancer DRGs ....................................................................................................................... Q-1 PSI Technical Specifications i Version 3.0a (May 1, 2006) AHRQ Quality Indicators Web Site: http://www.qualityindicators.ahrq.gov Patient Safety Indicators – Detailed Definitions For ICD-9-CM codes introduced after October 1995, the date of introduction is indicated after the code label, e.g., OCT 04. Complications of Anesthesia (PSI 1) Numerator: Discharges with ICD-9-CM diagnosis codes for anesthesia complications in any secondary diagnosis field. ICD-9-CM Anesthesia Complications diagnosis codes: Adverse effects in therapeutic use, other central nervous system depressants and anesthetics: E8763 ENDOTRACHEAL TUBE WRONGLY PLACE DURING ANESTHETIC PROCEDURE E9381 HALOTHANE E9382 OTHER GASEOUS ANESTHETICS E9383 INTRAVENOUS ANESTHETICS E9384 OTHER AND UNSPECIFIED GENERAL ANESTHETICS E9385 SURFACE AND INFILTRATION ANESTHETICS E9386 PERIPHERAL NERVE AND PLEXUS BLOCKING ANESTHETICS E9387 SPINAL ANESTHETICS E9389 OTHER AND UNSPECIFIED LOCAL ANESTHETICS Poisoning by other central nervous system depressants and anesthetics: 9681 HALOTHANE 9682 OTHER GASEOUS ANESTHETICS 9683 INTRAVENOUS ANESTHETICS 9684 OTHER AND UNSPECIFIED GENERAL ANESTHETICS 9687 SPINAL ANESTHETICS E8551 ACCIDENTAL POISONING, OTHER NERVOUS SYSTEM DEPRESSANTS Denominator: All surgical discharges, 18 years and older or MDC 14 (pregnancy, childbirth, and puerperium), defined by specific DRGs and an ICD-9-CM code for an operating room procedure. See Appendix A: Operating Room Procedure Codes See Appendix B: Surgical Discharge DRGs Exclude cases: with ICD-9-CM diagnosis codes for anesthesia complications (see Numerator) in the principal diagnosis field with codes for self-inflicted injury, poisoning due to anesthetics (E8551, 9681-4, 9687) and any diagnosis code for active drug dependence, or active nondependent abuse of drugs See Appendix L: Self-Inflicted Injury Diagnosis Codes Control-click (Word) or click (PDF) to view the Appendix. Links are provided to return to the PSI Detailed Definition. PSI Technical Specifications 1 Version 3.0a (May 1, 2006) AHRQ Quality Indicators Web Site: http://www.qualityindicators.ahrq.gov Complications of Anesthesia (PSI 1) ICD-9-CM Active Drug Dependence diagnosis codes: 30400 OPIOID TYPE DEPENDENCE - UNSPECIFIED 30401 OPIOID TYPE DEPENDENCE - CONTINUOUS 30402 OPIOID TYPE DEPENDENCE - EPISODIC 30410 BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC DEPENDENCE - UNSPECIFIED 30411 BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC DEPENDENCE - CONTINUOUS 30412 BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC DEPENDENCE - EPISODIC 30420 COCAINE DEPENDENCE - UNSPECIFIED 30421 COCAINE DEPENDENCE - CONTINUOUS 30422 COCAINE DEPENDENCE - EPISODIC 30430 CANNABIS DEPENDENCE - UNSPECIFIED 30431 CANNABIS DEPENDENCE - CONTINUOUS 30432 CANNABIS DEPENDENCE - EPISODIC 30440 AMPHETAMINE AND OTHER PSYCHO STIMULANT DEPENDENCE - UNSPECIFIED 30441 AMPHETAMINE AND OTHER PSYCHO STIMULANT DEPENDENCE - CONTINUOUS 30442 AMPHETAMINE AND OTHER PSYCHO STIMULANT DEPENDENCE - EPISODIC 30450 HALLUCINOGEN DEPENDENCE - UNSPECIFIED 30451 HALLUCINOGEN DEPENDENCE - CONTINUOUS 30452 HALLUCINOGEN DEPENDENCE - EPISODIC 30460 OTHER SPECIFIED DRUG DEPENDENCE - UNSPECIFIED 30461 OTHER SPECIFIED DRUG DEPENDENCE - CONTINUOUS 30462 OTHER SPECIFIED DRUG DEPENDENCE - EPISODIC 30470 COMBINATIONS OF OPIOID TYPE DRUG W/ ANY OTHER - UNSPECIFIED 30471 COMBINATIONS OF OPIOID TYPE DRUG W/ ANY OTHER - CONTINUOUS 30472 COMBINATIONS OF OPIOID TYPE DRUG W/ ANY OTHER - EPISODIC 30480 COMBINATIONS OF DRUG EXCLUDING OPIOID TYPE DRUG - UNSPECIFIED 30481 COMBINATIONS OF DRUG EXCLUDING OPIOID TYPE DRUG - CONTINUOUS 30482 COMBINATIONS OF DRUG EXCLUDING OPIOID TYPE DRUG - EPISODIC 30490 UNSPECIFIED DRUG DEPENDENCE - UNSPECIFIED 30491 UNSPECIFIED DRUG DEPENDENCE - CONTINUOUS 30492 UNSPECIFIED DRUG DEPENDENCE - EPISODIC ICD-9-CM Active Nondependent Abuse of Drugs diagnosis codes: 30520 CANNABIS ABUSE - UNSPECIFIED 30521 CANNABIS ABUSE - CONTINUOUS 30522 CANNABIS ABUSE - EPISODIC 30530 HALLUCINOGEN ABUSE - UNSPECIFIED 30531 HALLUCINOGEN ABUSE - CONTINUOUS 30532 HALLUCINOGEN ABUSE - EPISODIC 30540 BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC ABUSE - UNSPECIFIED 30541 BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC ABUSE - CONTINUOUS 30542 BARBITURATE AND
Recommended publications
  • Neurophysiologic Testing and Monitoring
    UnitedHealthcare® Commercial Medical Policy Neurophysiologic Testing and Monitoring Policy Number: 2021T0493Z Effective Date: January 1, 2021 Instructions for Use Table of Contents Page Community Plan Policy Coverage Rationale ........................................................................... 1 • Neurophysiologic Testing and Monitoring Applicable Codes .............................................................................. 2 Description of Services ..................................................................... 4 Medicare Advantage Coverage Summary Clinical Evidence ............................................................................... 6 • Neurophysiological Studies U.S. Food and Drug Administration ..............................................16 References .......................................................................................18 Policy History/Revision Information..............................................21 Instructions for Use .........................................................................22 Coverage Rationale Nerve Conduction Studies The following are proven and medically necessary: • Nerve conduction studies with or without late responses (e.g., F-wave and H-reflex tests) and neuromuscular junction testing when performed in conjunction with needle electromyography for any of the following known or suspected disorders: o Peripheral neuropathy/polyneuropathy (e.g., inherited, metabolic, traumatic, entrapment syndromes) o Plexopathy o Neuromuscular junction disorders (e.g.,
    [Show full text]
  • Multisectoral Academic Training Guide on Female Genital Mutilation/Cutting
    Multisectoral Academic Training Guide on Female Genital Mutilation/Cutting Directoras Adriana Kaplan y Laura Nuño Gómez Coordinadoras Magaly Thill y Nora Salas Seoane Multisectoral Academic Training Guide on Female Genital Mutilation/Cutting Multisectoral Academic Training Guide on Female Genital Mutilation/Cutting Directoras Adriana Kaplan y Laura Nuño Gómez Coordinadoras Magaly Thill y Nora Salas Seoane Neus Aliaga Sonia Núñez Puente Rut Bermejo Casado Laura Nuño Gómez Clara Carvalho Els Leye Giovanna Cavatorta Carla Moleiro Gily Coene Maya Pellicciari Ricardo Falcão Francesco Pompeo Lidia Fernández Montes Julia Ropero Carrasco Diana Fernández Romero Nora Salas Seoane Sabrina Flamini Cristina Santinho Michela Fusaschi Magaly Thill Cecilia Gallotti Valentina Vitale Adriana Kaplan Edición y revisión de la versión original en inglés Lucy Deegan Leirião This publication has been produced with the financial support of the Rights, Equality and Citizenship Programme 2014-2020 of the European Union. The contents of this publication are the sole responsibility of its authors and can in no way be taken to reflect the views of the European Commission. It is part of the Multisectoral Academic Programme to prevent and combat Female Genital Mutilation (FGM/C). © Los autores Editorial DYKINSON, S.L. Meléndez Valdés, 61 – 28015 Madrid Teléfono (+34) 91544 28 46 – (+34) 91544 28 69 e-mail: [email protected] http://www.dykinson.es http://www.dykinson.com ISBN: Preimpresión: Besing Servicios Gráfi cos, S.L. [email protected] Table of contents List of abbreviations ..................................................................................... 15 Institutions and authors ............................................................................... 17 Chapter I. Introduction to the Multisectoral Academic Training Guide on FGM/C .............................................................................. 25 Laura Nuño Gómez and Adriana Kaplan 1.
    [Show full text]
  • Female Genital Cosmetic Surgery Exceptional
    FEMALE GENITAL COSMETIC SURGERY EXCEPTIONAL FUNDING REQUIRED BaNES, Swindon and Wiltshire CCG (BSW) does not normally fund elective vaginal labial surgery, vaginoplasty or hymenorrhaphy. Clinicians must ensure there is a clear clinical rationale for any potential intervention, as all procedures that involve partial or total removal of the external female genitalia for non-clinical reasons are defined as Female Genital Mutilation and as such are against the law. (The Female Genital Mutilation Act of 2003) Clinicians must be alert to the possibility that some patients who seek revision surgery may do so as a result of previous interventions which are classed as unlawful under the Act. Background Labiaplasty A labiaplasty is a surgical procedure to reduce the size of the labia minora. Labiaplasty is generally a cosmetic procedure to change appearance alone and common consequence of childbirth is not sufficient reason to apply for funding. Labiaplasty is not normally supported or funded by the CCG. Vaginoplasty Non-reconstructive vaginoplasty or "vaginal rejuvenation" is used to restore vaginal tone and appearance. As this is generally considered a cosmetic procedure, vaginoplasty is not normally supported or funded by the CCG. Hymenorrhaphy Hymenorrhaphy, or hymen reconstruction surgery, is a cosmetic procedure and is not normally supported or funded by the CCG. This policy does not relate to reversal of female genital mutilation. This policy is informed by the NHS England (2013) Interim Clinical Commissioning Policy Labiaplasty, Vaginoplasty & Hymenorrhaphy. (Armed Forces Commissioning Policy Task and Finish Group) Reference: Policy Name Review Date Version BSW-CP046 Female Genital Cosmetic Surgery March 2023 4.1 .
    [Show full text]
  • Urology Services in the ASC
    Urology Services in the ASC Brad D. Lerner, MD, FACS, CASC Medical Director Summit ASC President of Chesapeake Urology Associates Chief of Urology Union Memorial Hospital Urologic Consultant NFL Baltimore Ravens Learning Objectives: Describe the numerous basic and advanced urology cases/lines of service that can be provided in an ASC setting Discuss various opportunities regarding clinical, operational and financial aspects of urology lines of service in an ASC setting Why Offer Urology Services in Your ASC? Majority of urologic surgical services are already outpatient Many urologic procedures are high volume, short duration and low cost Increasing emphasis on movement of site of service for surgical cases from hospitals and insurance carriers to ASCs There are still some case types where patients are traditionally admitted or placed in extended recovery status that can be converted to strictly outpatient status and would be suitable for an ASC Potential core of fee-for-service case types (microsurgery, aesthetics, prosthetics, etc.) Increasing Population of Those Aged 65 and Over As of 2018, it was estimated that there were 51 million persons aged 65 and over (15.63% of total population) By 2030, it is expected that there will be 72.1 million persons aged 65 and over National ASC Statistics - 2017 Urology cases represented 6% of total case mix for ASCs Urology cases were 4th in median net revenue per case (approximately $2,400) – behind Orthopedics, ENT and Podiatry Urology comprised 3% of single specialty ASCs (5th behind
    [Show full text]
  • Native Kidney Biopsy
    Mohammed E, et al., J Nephrol Renal Ther 2020, 6: 034 DOI: 10.24966/NRT-7313/100034 HSOA Journal of Nephrology & Renal Therapy Review Article Native Kidney Biopsy: An Introduction The burden of non communicable diseases has been a worldwide Update and Best Practice public health challenge, as chronic diseases compose 61% of global deaths and 49% of the global burden of diseases. Currently, many Evidence countries are encountering a fast transformation in the disease pro- file from first generation diseases such as infectious diseases to the encumbrance of non communicable diseases. In addition, Chronic Ehab Mohammed1, Issa Al Salmi1 *, Shilpa Ramaiah1 and Suad Hannawi2 Kidney Disease (CKD) is increasingly recognized as a global public health challenge as 10% of the global population is affected [1,2]. 1Nephrologist, The Renal Medicine Department, The Royal Hospital, Muscat, Oman The scarcity of well-trained renal pathologists, even in high-in- come countries, is a major obstacle to use of biopsy samples. The ISN 2Medicine Department, Ministry of Health and Prevention, Dubai, UAE is working worldwide to enhance development of local renal patholo- gy expertise. Levin et al stated that analysis of kidney biopsy samples can be used to stratify CKD into distinct subgroups of diseases based Abstract on specific histological patterns, when combined with the clinical pre- sentation [3]. Diabetes mellitus and hypertensive nephropathy are the Objectives: To Provide up-to-date guidelines for medical and nurs- commonly identified causes of End-Stage Kidney Disease (ESKD). ing staffs on the pre, during, and post care of a patient undergoing a Also, many patients with glomerulonephritis, systemic lupus erythe- percutaneous-kidney-biopsy-PKB.
    [Show full text]
  • 1311 Diploma in Medical Record Science Second
    [LD 0212] AUGUST 2013 Sub. Code: 1311 DIPLOMA IN MEDICAL RECORD SCIENCE SECOND YEAR PAPER II – INTERNATIONAL CLASSIFICATION OF DISEASES (ICD-10) & SURGICAL PROCEDURES (ICM-9CM) Q.P. Code : 841311 Time : Three Hours Maximum : 100 marks Answer ALL questions I Write appropriate codes using ICD -10 (30 x 1 = 30) 1. Therapeutic introduction of hand tendon. 2. Excision of major partial thickness of eyelid excision. 3. Interphalangeal arthrodesis of Toe. 4. Division of percutaneous spinal cord nerve tracts. 5. Transfusion of allograft bone aetriosus. 6. Rastelli operation of truncus arteriosus. 7. Pyoloric sphincter dilatation. 8. Stapling of radius epiphyseal plate. 9. Suture of hands fascia. 10. Suture of hand fascia. 11. Repair of anterior wall (abdomen) hernia. 12. Foreign body removal without incision in t o the brain. 13. Repair of Tetrology of fallot. 14. Frontal Sinusectomy. 15. Urethral sling suspension. 16. Bone shaft transfer. 17. Coil of aneuryum repair. 18. Sling suspension. 19. Radio isotope scanning, pituitary gland. 20. Spinal shunt removal. 21. Acute lung edema. Due to external agent. 22. Proximal end tibial closed fracture was riding a two wheeler-slip & fell down. 23. Thrombosed internal hemorrhoids. 24. Secondary hypertension due to renal disorder. 25. Old myocardial infarction. 26. Fall from high place, injured elbow. 27. Chronic venous (peripheral) insufficiency. 28. Acute myeloid leukemia. 29. Post-operative intestine obstruction. 30. Abnormal pregnancy. II Writes appropriate codes using ICS-9CM (20 x 2 = 40) 1. Pregnant women suffering from acute salphingo oophoritis. 2. Accidental intake of ferrous salt. 3. Sprain of lumbar spine as stuck by another person. 4.
    [Show full text]
  • Improved Preservation of Human Corneal Basement Membrane
    BritishJournal ofOphthalmology 1994; 78: 863-870 863 Improved preservation ofhuman corneal basement membrane following freezing of donor tissue for Br J Ophthalmol: first published as 10.1136/bjo.78.11.863 on 1 November 1994. Downloaded from epikeratophakia Robert D Young, W John Armitage, Paul Bowerman, Stuart D Cook, David L Easty Abstract States, good results continue to be achieved by Current methods for the production of the small number ofBritish surgeons performing lenticules for epikeratophakia involve rapid the technique.4 However, no comprehensive freezing, cryolathing, and slow warming of the account of its long term outcome has yet been donor cornea. We have found that this pro- published. cedure causes structural damage to the Several complications resulting in the failure epithelial basement membrane in the donor of epikeratophakia have been reported, includ- cornea which may subsequently contribute to ing infection, graft dehiscence, persistent inter- poor postoperative re-epithelialisation of the face haze or opacity, ulceration, and imperfect implant, leading to graft failure. Endeavouring re-epithelialisation. Among these, the failure of to overcome these problems, the effects of host epithelial cells to migrate over and re- cryoprotection of donor cornea were investi- surface the anterior face of the grafted tissue gated, using dimethyl sulphoxide, in conjunc- continues to be the major reason for the removal tion with different cooling and warming rates ofepikeratophakia lenticules.'-'0 as part of the protocol for cryolathing. The Epithelial healing is itselfa complex phenome- structural integrity of the epithelial basement non involving mitosis of host cells at the graft membrane zone (BMZ) was then assessed by periphery, centripetal migration, and attach- electron microscopy and by immunofluores- ment.
    [Show full text]
  • Reversible Signal Abnormalities in the Hippocampus and Neocortex After Prolonged Seizures
    Reversible Signal Abnormalities in the Hippocampus and Neocortex after Prolonged Seizures Stephen Chan, Steven S. M. Chin, Krishnan Kartha, Douglas R. Nordli, Robert R. Goodman, Timothy A. Pedley, and Sadek K. Hilal PURPOSE: To investigate the phenomenon of reversible increased signal intensity of medial temporal lobe structures and cerebral neocortex seen on MR images of six patients with recent prolonged seizure activity. METHODS: After excluding patients with known causes of reversible signal abnormalities (such as hypertensive encephalopathy), we retrospectively reviewed the clinical findings and MR studies of six patients whose MR studies showed reversible signal abnor- malities. MR pulse sequences included T2-weighted spin-echo coronal views or conventional short-tau inversion-recovery coronal images of the temporal lobes. RESULTS: All six MR studies showed increased signal intensity within the medial temporal lobe, including the hippocampus in five studies. All follow-up MR examinations showed partial or complete resolution of the hyperin- tensity within the medial temporal lobe and the neocortex. In one patient, results of a brain biopsy revealed severe cerebral cortical gliosis. Temporal lobectomy performed 4 years later showed moderate cortical gliosis and nonspecific hippocampal cell loss and gliosis. CONCLUSION: Sig- nificant hyperintensity within the temporal lobe is demonstrable on MR images after prolonged seizure activity, suggestive of seizure-induced edema or gliosis. Damage to medial temporal lobe structures by prolonged seizure activity indicates a possible mechanism of epileptogenic disorders. Index terms: Brain, magnetic resonance; Brain, temporal lobe; Hippocampus; Seizures AJNR Am J Neuroradiol 17:1725–1731, October 1996 Prolonged seizure activity is associated with character of the acute neuronal loss in the hip- long-lasting neurologic damage and even death pocampus seen after an episode of status epi- in humans (1–3); prompt treatment is required lepticus is different from the neuronal loss and to forestall irreversible changes (4).
    [Show full text]
  • Guidelines on Paediatric Urology S
    Guidelines on Paediatric Urology S. Tekgül (Chair), H.S. Dogan, E. Erdem (Guidelines Associate), P. Hoebeke, R. Ko˘cvara, J.M. Nijman (Vice-chair), C. Radmayr, M.S. Silay (Guidelines Associate), R. Stein, S. Undre (Guidelines Associate) European Society for Paediatric Urology © European Association of Urology 2015 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Aim 7 1.2 Publication history 7 2. METHODS 8 3. THE GUIDELINE 8 3A PHIMOSIS 8 3A.1 Epidemiology, aetiology and pathophysiology 8 3A.2 Classification systems 8 3A.3 Diagnostic evaluation 8 3A.4 Disease management 8 3A.5 Follow-up 9 3A.6 Conclusions and recommendations on phimosis 9 3B CRYPTORCHIDISM 9 3B.1 Epidemiology, aetiology and pathophysiology 9 3B.2 Classification systems 9 3B.3 Diagnostic evaluation 10 3B.4 Disease management 10 3B.4.1 Medical therapy 10 3B.4.2 Surgery 10 3B.5 Follow-up 11 3B.6 Recommendations for cryptorchidism 11 3C HYDROCELE 12 3C.1 Epidemiology, aetiology and pathophysiology 12 3C.2 Diagnostic evaluation 12 3C.3 Disease management 12 3C.4 Recommendations for the management of hydrocele 12 3D ACUTE SCROTUM IN CHILDREN 13 3D.1 Epidemiology, aetiology and pathophysiology 13 3D.2 Diagnostic evaluation 13 3D.3 Disease management 14 3D.3.1 Epididymitis 14 3D.3.2 Testicular torsion 14 3D.3.3 Surgical treatment 14 3D.4 Follow-up 14 3D.4.1 Fertility 14 3D.4.2 Subfertility 14 3D.4.3 Androgen levels 15 3D.4.4 Testicular cancer 15 3D.5 Recommendations for the treatment of acute scrotum in children 15 3E HYPOSPADIAS 15 3E.1 Epidemiology, aetiology and pathophysiology
    [Show full text]
  • Diagnostic Nasal/Sinus Endoscopy, Functional Endoscopic Sinus Surgery (FESS) and Turbinectomy
    Medical Coverage Policy Effective Date ............................................. 7/10/2021 Next Review Date ....................................... 3/15/2022 Coverage Policy Number .................................. 0554 Diagnostic Nasal/Sinus Endoscopy, Functional Endoscopic Sinus Surgery (FESS) and Turbinectomy Table of Contents Related Coverage Resources Overview .............................................................. 1 Balloon Sinus Ostial Dilation for Chronic Sinusitis and Coverage Policy ................................................... 2 Eustachian Tube Dilation General Background ............................................ 3 Drug-Eluting Devices for Use Following Endoscopic Medicare Coverage Determinations .................. 10 Sinus Surgery Coding/Billing Information .................................. 10 Rhinoplasty, Vestibular Stenosis Repair and Septoplasty References ........................................................ 28 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence
    [Show full text]
  • Photorefractive Keratectomy for Correction of Epikeratophakia
    CASE REPORTS AND SMALL CASE SERIES high myopia resulting from poste- results might be related to the pre- Photorefractive Keratectomy rior lenticonus. Postsurgical refrac- existing corneal stromal abnormali- for Correction of tion was stable for 8 years, then a ties in their patients, which were not Epikeratophakia Regression rapid myopic regression of the epi- observed in our group. Thus, PRK keratophakic lenses was observed can effectively be used to treat epi- Excimer laser photorefractive kera- the following year (Table). In- keratophakic regressed lenses in a se- tectomy (PRK) is widely used for the stead of removing the failed epikera- lected group of patients in whom correction of myopia, astigmatism, tophakic lenses, we performed PRK both the epikeratograft and the sur- and hyperopia.1,2 It has also been on the eyes. rounding cornea are clear. This used for correction of astigmatism method eliminates the need for re- after penetrating keratoplasty.3 Results. Two and a half years after moval of the epikeratograft and ex- Epikeratophakia has been used PRK, the refraction in all 4 eyes is posing the patient to the risks of suc- in the treatment of nontolerant con- stable and the epigrafts are clear. The cessive penetrating keratoplasty. tact lens keratoconous patients.4,5 Table presents the refraction and vi- The epigrafts were made from ma- sual acuity results for the eyes be- Hirsh Ami, MD chined corneal tissue that was found fore PRK and at 3 months, 1 year, Solberg Yoram, MD, PhD unsuitable for penetrating kerato- and 21⁄2 years after PRK. No haze has Cahana Michael, MD plasty.
    [Show full text]
  • ANMC Specialty Clinic Services
    Cardiology Dermatology Diabetes Endocrinology Ear, Nose and Throat (ENT) Gastroenterology General Medicine General Surgery HIV/Early Intervention Services Infectious Disease Liver Clinic Neurology Neurosurgery/Comprehensive Pain Management Oncology Ophthalmology Orthopedics Orthopedics – Back and Spine Podiatry Pulmonology Rheumatology Urology Cardiology • Cardiology • Adult transthoracic echocardiography • Ambulatory electrocardiology monitor interpretation • Cardioversion, electrical, elective • Central line placement and venous angiography • ECG interpretation, including signal average ECG • Infusion and management of Gp IIb/IIIa agents and thrombolytic agents and antithrombotic agents • Insertion and management of central venous catheters, pulmonary artery catheters, and arterial lines • Insertion and management of automatic implantable cardiac defibrillators • Insertion of permanent pacemaker, including single/dual chamber and biventricular • Interpretation of results of noninvasive testing relevant to arrhythmia diagnoses and treatment • Hemodynamic monitoring with balloon flotation devices • Non-invasive hemodynamic monitoring • Perform history and physical exam • Pericardiocentesis • Placement of temporary transvenous pacemaker • Pacemaker programming/reprogramming and interrogation • Stress echocardiography (exercise and pharmacologic stress) • Tilt table testing • Transcutaneous external pacemaker placement • Transthoracic 2D echocardiography, Doppler, and color flow Dermatology • Chemical face peels • Cryosurgery • Diagnosis
    [Show full text]